DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Optimal dosage of cyclopentolate 1% for complete cycloplegia: A randomized clinical trial.

Author(s): Bagheri A, Givrad S, Yazdani S, Reza Mohebbi M

Affiliation(s): Shahid Beheshti University of Medical Science, Tehran - Iran.

Publication date & source: 2007-05, Eur J Ophthalmol., 17(3):294-300.

PURPOSE. To determine the optimal dosage of cyclopentolate for adequate cycloplegia with minimal side effects. METHODS. A prospective randomized clinical trial of patients 3.5 to 20 years of age referred to a strabismus clinic during a 1-year period. Eligible patients were randomly divided into three groups. In Group 1, the cycloplegic effect of one drop of cyclopentolate was com-pared with two drops; in Group 2, the effect of two drops was compared with three drops; and in Group 3, the effect of one drop was compared with three drops. RESULTS. This study includes 192 eyes of 96 patients with a mean age of 11.0 +/- 5.7 years. Strabismus was present in 43 patients (44.8%). A total of 146 patients (76%) were hyperopic, 33 (17.2%) were myopic, and 13 (6.8%) were slightly hyperopic or myopic at the two stages of the study. Overall, only 16 eyes, including 9 eyes in Group 1 (16.4%), 2 eyes in Group 2 (3.2%), and 5 eyes in Group 3 (8.6%), had >/= 0.5 D difference in pherical equivalent refractive error at two stages of the study; however, intergroup differences were not statistically significant (p=0.16, chi-square test). Within each group, the percentage of eyes with <0.5 D difference was significantly greater than those with <0.5 D difference (p<0.001in all three groups, binomial test). Side effects were more prevalent using more frequent drops. CONCLUSIONS. A single drop of cyclopentolate 1% suffices for cycloplegic refraction. There were less frequent side effects using one drop of cyclopentolate, compared to two or three drops.

Page last updated: 2007-06-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017